Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CMMB Chemomab Therapeutics	$0.89 +0.6%	$1.09	$0.87 ▼ $2.55	$16.69M	0.52	114,253 shs	302,411 shs
DARE Dare Bioscience	$2.12 +1.0%	$2.45	$1.83 ▼ $9.19	$28.31M	1.11	253,827 shs	155,086 shs
PMN Promis Neurosciences	$0.54 -2.4%	$0.59	$0.38 ▼ $1.59	$28.44M	-0.04	1.07 million shs	334,222 shs
VIVS VivoSim Labs	$2.11 +6.6%	$1.78	$1.41 ▼ $21.96	$5.15M	0.94	45,311 shs	46,081 shs

Beginner's Guide To Retirement Stocks

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CMMB Chemomab Therapeutics	+0.56%	-4.30%	-19.09%	-34.80%	-27.05%
DARE Dare Bioscience	+0.95%	-3.64%	-20.30%	-26.90%	-40.11%
PMN Promis Neurosciences	-2.39%	-13.14%	-39.10%	+6.12%	-56.43%
VIVS VivoSim Labs	+6.57%	+19.21%	-9.83%	+210,999,900.00%	+210,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CMMB Chemomab Therapeutics	3.5271 of 5 stars	3.5	5.0	0.0	0.0	3.3	1.7	0.6
DARE Dare Bioscience	2.5683 of 5 stars	3.5	5.0	0.0	0.0	2.5	0.0	0.0
PMN Promis Neurosciences	2.4376 of 5 stars	3.5	5.0	0.0	0.0	0.0	0.8	0.6
VIVS VivoSim Labs	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CMMB Chemomab Therapeutics	3.00	Buy	$8.50	855.06% Upside
DARE Dare Bioscience	3.00	Buy	$12.00	466.04% Upside
PMN Promis Neurosciences	3.00	Buy	$4.33	708.61% Upside
VIVS VivoSim Labs	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest VIVS, DARE, PMN, and CMMB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/21/2025	PMN Promis Neurosciences	Leede Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Moderate Buy
7/14/2025	PMN Promis Neurosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$4.00
7/14/2025	PMN Promis Neurosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$4.00

(Data available from 8/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CMMB Chemomab Therapeutics	N/A	N/A	N/A	N/A	$0.51 per share	N/A
DARE Dare Bioscience	$10K	2,857.76	N/A	N/A	($0.94) per share	-2.26
PMN Promis Neurosciences	N/A	N/A	N/A	N/A	($0.01) per share	N/A
VIVS VivoSim Labs	$140K	39.19	N/A	N/A	$3.67 per share	0.57

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CMMB Chemomab Therapeutics	-$13.94M	-$0.59	N/A	N/A	N/A	N/A	-94.71%	-76.53%	N/A
DARE Dare Bioscience	-$4.05M	-$2.14	N/A	N/A	N/A	N/A	N/A	-103.70%	N/A
PMN Promis Neurosciences	$2.78M	-$0.21	N/A	N/A	N/A	N/A	-266.69%	-131.59%	N/A
VIVS VivoSim Labs	-$2.48M	-$10.20	N/A	∞	N/A	-1,396.48%	-32.95%	-21.31%	N/A

Latest VIVS, DARE, PMN, and CMMB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	CMMB Chemomab Therapeutics	-$0.20	-$0.09	+$0.11	-$0.09	N/A	N/A
8/14/2025	Q2 2025	DARE Dare Bioscience	-$0.55	-$0.45	+$0.10	-$0.45	$0.14 million	($0.02) million
8/13/2025	Q2 2025	PMN Promis Neurosciences	-$0.22	-$0.29	-$0.07	-$0.29	N/A	N/A
8/12/2025	Q1 2026	VIVS VivoSim Labs	N/A	-$1.14	N/A	-$1.14	N/A	$0.04 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CMMB Chemomab Therapeutics	N/A	N/A	N/A	N/A	N/A
DARE Dare Bioscience	N/A	N/A	N/A	N/A	N/A
PMN Promis Neurosciences	N/A	N/A	N/A	N/A	N/A
VIVS VivoSim Labs	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CMMB Chemomab Therapeutics	N/A	7.42	5.33
DARE Dare Bioscience	N/A	0.34	0.56
PMN Promis Neurosciences	N/A	0.97	0.97
VIVS VivoSim Labs	N/A	4.52	4.52

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CMMB Chemomab Therapeutics	46.05%
DARE Dare Bioscience	6.70%
PMN Promis Neurosciences	50.13%
VIVS VivoSim Labs	8.23%

Insider Ownership

Company	Insider Ownership
CMMB Chemomab Therapeutics	11.91%
DARE Dare Bioscience	4.80%
PMN Promis Neurosciences	6.11%
VIVS VivoSim Labs	3.72%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CMMB Chemomab Therapeutics	20	18.86 million	16.61 million	Not Optionable
DARE Dare Bioscience	30	13.48 million	8.60 million	Not Optionable
PMN Promis Neurosciences	5	51.81 million	30.69 million	Not Optionable
VIVS VivoSim Labs	20	2.60 million	2.50 million	N/A

VIVS, DARE, PMN, and CMMB Headlines

Recent News About These Companies

VivoSim Labs, Inc.: VivoSim Labs Appoints Tony Lialin as Chief Commercial Officer

August 14, 2025 | finanznachrichten.de

VivoSim appoints Lialin as Chief Commercial Officer

August 14, 2025 | msn.com

VivoSim Labs, Inc. Appoints Tony Lialin as Chief Commercial Officer to Drive Growth in 3D Drug Testing Services

August 14, 2025 | quiverquant.comQ

VivoSim Labs Appoints Tony Lialin as Chief Commercial Officer

August 14, 2025 | financialpost.comF

VivoSim Labs Appoints Tony Lialin as Chief Commercial Officer

August 14, 2025 | globenewswire.com

VivoSim: Fiscal Q1 Earnings Snapshot

August 12, 2025 | timesunion.comT

New MarketBeat Followers Over Time

Media Sentiment Over Time

VIVS, DARE, PMN, and CMMB Company Descriptions

Chemomab Therapeutics NASDAQ:CMMB

$0.89 +0.01 (+0.56%)

Closing price 08/22/2025 03:59 PM Eastern

Extended Trading

$0.87 -0.02 (-2.25%)

As of 08/22/2025 07:59 PM Eastern

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel.

Dare Bioscience NASDAQ:DARE

$2.12 +0.02 (+0.95%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$2.20 +0.08 (+3.77%)

As of 08/22/2025 07:59 PM Eastern

Daré Bioscience, Inc., a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older. It is developing Ovaprene, a hormone-free, monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia on demand for the treatment of female sexual arousal disorder; DARE-HRT1 to treat moderate to-severe vasomotor symptoms in menopausal hormone therapy; DARE-VVA1 for the treatment of moderate-to-severe dyspareunia or pain during sexual intercourse; and DARE-CIN to treat cervical intraepithelial neoplasia and other human papillomavirus related pathologies. The company is also developing DARE-PDM1 for the treatment of primary dysmenorrhea; DARE-204 and DARE-214, an injectable formulations contraception of etonogestrel designed to provide contraception over 6-month and 12-month periods; DARE-FRT1, an intravaginal ring designed to deliver bio-identical progesterone for luteal phase support as part of an in vitro fertilization treatment plan; and DARE-PTB1 for the prevention of preterm birth. In addition, it is developing DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design that controlled contraceptive option; DARE-LBT, a novel hydrogel formulation for vaginal delivery of live biotherapeutics to support vaginal health; DARE-GML, a multi-target antimicrobial agent; DARE-RH1, a novel approach to non-hormonal contraception for men and women by targeting the CatSper ion channel; and DARE-PTB2 for the prevention and treatment of idiopathic preterm birth through inhibition of a stress response protein. Daré Bioscience, Inc. is headquartered in San Diego, California.

Promis Neurosciences NASDAQ:PMN

$0.54 -0.01 (-2.39%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$0.54 +0.00 (+0.39%)

As of 08/22/2025 07:18 PM Eastern

ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates comprise of PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a TDP-43; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.

VivoSim Labs NASDAQ:VIVS

$2.11 +0.13 (+6.57%)

As of 08/22/2025 03:59 PM Eastern

Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive human liver tissue and ExVive human kidney tissue used for predictive preclinical testing of drug compounds. It is also developing in vivo liver tissues to treat end-stage liver, life-threatening, and orphan diseases. The company was incorporated in 2007 and is headquartered in Solana Beach, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time